iseases that struggle to attract sufficient support from private investors or aid agencies,??? the Financial Times writes. ???The hybrid mechanism taps new sources of funding for late-stage testing and approval of drugs, vaccines, diagnostics and other products designed to tackle infectious diseases such as HIV, malaria, tuberculosis and diarrhea in low-income countries,??? the newspaper notes, ad